RBM39 degrader therapeutic - SEED Therapeutics
Latest Information Update: 30 May 2024
At a glance
- Originator Seed Therapeutics
- Class Antineoplastics
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 May 2024 SEED Therapeutics plans a First-in Human trial for Cancer (PO) in 2025 (SEED Therapeutics pipeline, May 2024)
- 22 May 2024 SEED Therapeutics has patent protection for RBM39 degrader therapeutic (SEED Therapeutics pipeline, May 2024)
- 16 May 2024 Preclinical trial in Cancer in USA (PO) before May 2024